IQVIA Holdings Inc
NYSE:IQV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IQVIA Holdings Inc
Operating Income
IQVIA Holdings Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$8.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Waters Corp
NYSE:WAT
|
Operating Income
$800.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Operating Income
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
IQVIA Holdings Inc
Glance View
In the world of healthcare, IQVIA Holdings Inc. emerges as a formidable player, seamlessly blending data analytics with the imperative of human well-being. Born from the merger of IMS Health and Quintiles in 2016, IQVIA stands at the intersection of technology and life sciences, leveraging vast amounts of health-related data to facilitate more informed decisions in drug development and patient care. The company's vast repository consists of a complex tapestry of dynamic insights from around the globe, which it transforms using sophisticated analytical tools. This technical prowess enables IQVIA to offer solutions that span clinical trials, health information services, and advanced analytics, creating substantial value for pharmaceutical and life sciences companies. At the heart of IQVIA’s revenue model lies its ability to provide strategic services that reduce the time and cost associated with the development of new pharmaceuticals. By offering an integrated suite of services from the initial phases of drug research to post-market monitoring, IQVIA assists its clients in navigating regulatory landscapes and commercializing their products effectively. Its expansive technological infrastructure does not just aid in drug development but also enhances patient engagement, creating digital pathways for more personalized healthcare solutions. Thus, IQVIA earns its keep by not only selling information but also by offering transformative insights that sharpen the competitive edge for its clients in the ever-evolving healthcare sector.
See Also
What is IQVIA Holdings Inc's Operating Income?
Operating Income
2.3B
USD
Based on the financial report for Dec 31, 2025, IQVIA Holdings Inc's Operating Income amounts to 2.3B USD.
What is IQVIA Holdings Inc's Operating Income growth rate?
Operating Income CAGR 10Y
13%
Over the last year, the Operating Income growth was 1%. The average annual Operating Income growth rates for IQVIA Holdings Inc have been 8% over the past three years , 24% over the past five years , and 13% over the past ten years .